Rainmed Medical Limited Share Price

Equities

2297

KYG7360A1094

Advanced Medical Equipment & Technology

Market Closed - Hong Kong S.E. 09:08:20 26/04/2024 BST 5-day change 1st Jan Change
0.153 HKD -7.27% Intraday chart for Rainmed Medical Limited -11.05% -64.42%

Financials

Sales 2021 81.2M 11.21M 87.73M 897M Sales 2022 83.6M 11.54M 90.32M 924M Capitalization 1.6B 221M 1.73B 17.67B
Net income 2021 -634M -87.5M -685M -7.01B Net income 2022 -1.35B -186M -1.45B -14.88B EV / Sales 2021 * -
Net Debt 2021 819M 113M 885M 9.05B Net cash position 2022 550M 75.9M 594M 6.08B EV / Sales 2022 12.5 x
P/E ratio 2021 *
-
P/E ratio 2022
-0.91 x
Employees 406
Yield 2021 *
-
Yield 2022
-
Free-Float 25.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day-7.27%
1 week-11.05%
Current month-30.45%
1 month-33.19%
3 months-55.65%
6 months-75.32%
Current year-64.42%
More quotes
1 week
0.14
Extreme 0.142
0.17
1 month
0.14
Extreme 0.14
0.22
Current year
0.14
Extreme 0.14
0.46
1 year
0.14
Extreme 0.14
1.24
3 years
0.14
Extreme 0.14
6.10
5 years
0.14
Extreme 0.14
6.10
10 years
0.14
Extreme 0.14
6.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 09/12/21
Chief Executive Officer 46 31/12/13
Director of Finance/CFO 41 09/12/21
Members of the board TitleAgeSince
Director/Board Member 52 09/12/21
Director/Board Member 41 09/12/21
Chief Executive Officer 46 31/12/13
More insiders
Date Price Change Volume
26/04/24 0.153 -7.27% 191,000
25/04/24 0.165 0.00% 20,000
24/04/24 0.165 0.00% 0
23/04/24 0.165 0.00% 10,000
22/04/24 0.165 -4.07% 66,000

Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am

More quotes
Rainmed Medical Ltd is a China-based investment holding company. The Company is primarily engaged in research and development, manufacturing and commercialization of medical instrument related to coronary angiography-derived fractional flow reserve (caFFR) system and coronary angiography-derived index of microvascular resistance (caIMR) system. The Company’s core products, caFFR system and caIMR system, are innovative medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. The Company mainly operates its businesses in the domestic and overseas markets.
More about the company